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Summary 
Background Palonosetron has demonstrated efficacy in the prevention of chemotherapy-
induced nausea and vomiting (CINV) in adult patients undergoing moderately or highly 
emetogenic chemotherapy. This phase 3 study evaluated the efficacy and safety of 
palonosetron versus ondansetron in the prevention of CINV in paediatric patients.   
 
Methods In this multicentre, multinational, double-blind study, paediatric patients aged 0–
<17 years, naïve or non-naïve to chemotherapy and scheduled to undergo moderately or 
highly emetogenic chemotherapy for the treatment of malignant disease were randomised 
centrally 1:1:1 to receive up to four cycles of 10 or 20 µg/kg palonosetron on day 1, or three 
150 µg/kg doses of ondansetron on day 1, scheduled 4 hours apart, according to a static 
central permuted block randomisation scheme by an interactive web response system. 
Randomisation was stratified according to age and emetogenicity. The primary endpoint was 
complete response (no vomiting, retching, or use of rescue medication) during the acute 
phase (0–24 hours post-chemotherapy) of the first on-study chemotherapy cycle, as 
assessed in the population of randomly assigned patients who received moderately or highly 
emetogenic chemotherapy and an active study drug. Safety was assessed, according to 
treatment received, by adverse events, 12-lead electrocardiograms, laboratory and physical 
assessments, and vital signs. The study, registered with the ClinicalTrials.gov, number 
NCT01442376, has now been completed. 
 
Findings Between September 12, 2011, and October 26, 2012, 502 patients were 
randomised to receive 10 µg/kg palonosetron (n=169), 20 µg/kg palonosetron (n=169), or 
ondansetron (n=164), 493 of whom were included in the efficacy analysis. Most patients 
(388 [79%] of 493) had previously received chemotherapy and 271 [55%] of 493 received 
concomitant corticosteroids. Complete responses were recorded in 90 (54·2%) of 166 
patients receiving 10 µg/kg palonosetron, 98 (59·4%) of 165 receiving 20 µg/kg 
palonosetron, and 95 (58·6%) of 162 receiving ondansetron. Non-inferiority (δ=-15%) versus 
ondansetron was demonstrated for 20 µg/kg palonosetron (weighted sum of difference in 
complete response rates=0·36%, 97·5% Cl -11·7–12·4; p=0·0022). In the first on-study 
treatment cycle, treatment-emergent adverse events were reported in 134 (80·2%) of 166 
patients receiving 10 µg/kg palonosetron, 113 (69·3%) of 165 receiving 20 µg/kg 
palonosetron, and 134 (81·7%) of 162 receiving ondansetron. The most common drug-
related treatment emergent adverse events were nervous system disorders, primarily 
headache. Drug-related reports of electrocardiogram QT prolonged and sinus tachycardia 
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were less frequent in patients receiving palonosetron than ondansetron and raised no clinical 
concerns. The incidence of serious adverse events in the first on-study treatment cycle was 
lower in the 20 µg/kg palonosetron group (43 [26·4%] of 163 patients) than the 10 µg/kg 
palonosetron group (52 [31·1%] of 167 patients), and the ondansetron group (55 [33·5%] of 
164 patients). 
 
Interpretation Non-inferiority was demonstrated for 20 µg/kg palonosetron during the acute 
phase of the first on-study chemotherapy cycle. Electrocardiographic investigations and 
adverse event monitoring raised no concerns, demonstrating that palonosetron is safe in 
paediatric patients. 20 µg/kg palonosetron is now indicated by the European Medicines 
Agency for the prevention of CINV in paediatric patients aged 1 month to 17 years.  
 
Funding Helsinn Healthcare.
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Introduction 
 
Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing side-
effect of moderately and highly emetogenic chemotherapy regimens.1-3 Adult patients in 
whom CINV is left uncontrolled experience a severe deterioration in their quality of life and 
may experience malnourishment, anxiety, and depression. Fear of CINV is sufficient for 
many patients to postpone or even refuse potentially life-saving treatment.3-6 However, 
antiemetics can improve quality of life, increase treatment compliance and effectiveness, 
and therefore improve patient outcome.7-9 Antiemetics counter CINV by antagonising the 5-
hydroxytryptamine subtype 3 (5-HT3) receptor or the neurokinin-1 (NK1) receptor. Currently, 
in adult patients undergoing highly emetogenic chemotherapy, the administration of a 5-HT3 
receptor antagonist alongside the NK1 receptor antagonist, aprepitant, and dexamethasone 
is recommended for the treatment of acute CINV.10,11 For patients undergoing a moderately 
emetogenic chemotherapy regimen, palonosetron hydrochloride (Aloxi®, palonosetron; a 5-
HT3 receptor antagonist [Pierre Fabre Medicament Production, Idron, France]) plus 
dexamethasone is recommended.11_ENREF_10  
 
In paediatric patients, at the time of study design, Multinational Association of Supportive 
Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO) guidelines 
recommended prophylactic antiemetic therapy comprising a 5-HT3 receptor antagonist and 
dexamethasone to prevent acute CINV in patients scheduled to receive moderately or highly 
emetogenic chemotherapy.2 In later guidance, the Pediatric Oncology Group of Ontario 
(POGO) Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic 
Medication in Pediatric Cancer Patients recommended that children scheduled to receive 
highly emetogenic therapy should receive antiemetic prophylactic therapy of ondansetron or 
granisetron plus dexamethasone and aprepitant (≥12 years of age and receiving 
antineoplastic agents not known to interact with aprepitant) or ondansetron or granisetron 
plus dexamethasone (<12 years of age or receiving aprepitant interacting agents).12 For 
patients scheduled to receive moderately emetogenic chemotherapy, the recommendation in 
the POGO guidelines is that patients should receive ondansetron or granisetron plus 
dexamethasone._ENREF_12 
 
In adult patients receiving moderately emetogenic chemotherapy palonosetron has been 
shown to be superior as a single agent to ondansetron or dolasetron at preventing both 
acute and delayed CINV.13-15_ENREF_12 Palonosetron has also been shown to have greater 
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receptor selectivity, longer duration of action, and unique structural characteristics compared 
with other 5-HT3 receptor antagonists.
13,16-20 Palonosetron also appears to have an 
advantageous safety profile compared with ondansetron, granisetron, dolasetron, and 
tropisetron, which have been associated with electrocardiographic changes and arrhythmias, 
sometimes leading to the potentially fatal heart rhythm torsades de pointes.13,14,21-24 
Palonosetron has been shown not to cause arrhythmias or symptomatic electrocardiographic 
changes.25-27  
 
The present study was designed to assess the efficacy and safety of two intravenous doses 
of palonosetron (10 and 20 µg/kg) in paediatric patients with cancer aged from new-born (full 
term; ≥37 weeks) to <17 years, scheduled to undergo moderately or highly emetogenic 
chemotherapy. The primary objective of this study was to demonstrate in paediatric patients 
the non-inferiority of palonosetron, versus ondansetron, during the acute phase of the first 
on-study chemotherapy cycle. 
 
 
Methods 
 
Study design and participants 
This randomised, multinational, phase 3 study was done at 71 sites in the United States, 
Latin America, Western and Eastern Europe, and Russia. Eligible patients were aged from 
newborn (full term; ≥37 weeks) to less than 17 years, with a bodyweight of ≥3·2 kg, naïve or 
non-naïve to chemotherapy, scheduled to receive moderately or highly emetogenic 
chemotherapy (at the time of study design, a specific paediatric classification system was 
not available; agents designated in these risk groups for our study are listed in appendix p 1) 
on study day 1 (of a single-day regimen, or day 1 of a multiple-day regimen), for 
histologically, cytologically or in the case of brain tumours imaging-confirmed malignant 
disease. Eastern Cooperative Oncology Group performance status ≤2 was required in 
patients aged ≥10 years. For patients with known hepatic impairment (defined as aspartate 
aminotransferase >2·5 x upper limit of normal [ULN] or alanine aminotransferase >2·5 x ULN 
or total bilirubin >1·5 x ULN), known renal impairment (defined as creatinine >1·5 x ULN) or 
known history of or predisposition to cardiac abnormalities, inclusion was permitted if in the 
site investigator’s opinion, the existence of any such condition should not have jeopardized 
patient safety during the study. The use of any corticosteroid included in a chemotherapeutic 
regimen or to reduce intracranial pressure was permitted. The main exclusion criteria were: 
patients suffering from ongoing vomiting from any organic aetiology (including patients with 
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history of gastric outlet obstruction or intestinal obstruction due to adhesions or volvulus); 
patients with a history of gastric outlet or intestinal obstruction; patients who suffered 
vomiting, retching or nausea within the 24 hours prior to study drug administration; patients 
who had received any drug with a potential antiemetic effect within the 24 hours prior to 
treatment initiation (prior use of domperidone or metoclopramide was excluded; for details of 
all prohibited drugs, see appendix p 2); patients who had received total body irradiation or 
radiotherapy of the upper abdomen, cranium, craniospinal regions, or pelvis within one week 
of study entry; patients with baseline prolongation of the QTc interval >460 ms (this 
threshold was set following a request from the UK Medicines & Healthcare products 
Regulatory Agency that we define an acceptable maximal QTc length in relation to patient 
eligibility).  
 
The study was conducted in accordance with the Declaration of Helsinki (2008) and the 
International Conference on Harmonisation of Technical Requirements of Pharmaceuticals 
for Human Use (ICH) E6 guideline. Approval was obtained from the appropriate International 
Ethics Committees, Institutional Review Boards, and Regulatory Authorities, prior to study 
initiation. Written informed consent was obtained from parent(s)/legal guardian(s) prior to 
enrolment. For patients of appropriate age and maturity, signed assent forms were obtained 
in compliance with local laws and regulations. 
 
Randomisation and masking 
Eligible patients were randomised via an interactive web response system (IWRS) that 
assigned patients to treatment groups using a computer-generated randomisation schedule, 
stratified (as requested by the United States Food and Drug Administration [FDA]) by 
emetogenicity of chemotherapy (moderately/highly emetogenic) and age group (<2 years; 2 
years up to <6 years; 6 years up to <12 years; 12 years up to <17 years) through static 
central permuted blocks.  
 
The study was conducted in a double-blind, double-dummy manner. The IWRS provider and 
a designated Helsinn Healthcare SA employee retained master copies of the randomisation 
codes in a secure fashion to ensure blinding. Project team members involved in data 
collection and analysis, and members of the investigator’s team, had no access to the 
randomisation codes. Packaging and labelling of the study drugs were carried out in 
accordance with all applicable regulatory and legal requirements. All kits were identical in 
appearance with the exception of the kit number. The double-dummy design was 
accomplished by using the placebo formulation for palonosetron (identical to the active 
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formulation but without palonosetron and EDTA), and isotonic saline solution as the placebo 
for ondansetron.  
 
Procedures 
Patients were randomised to one of the following treatment groups: 10 µg/kg palonosetron, 
up to a maximum dose of 0·75 mg, administered 30 ± 5 minutes before chemotherapy as a 
15-minute intravenous infusion; 20 µg/kg palonosetron, up to a maximum dose of 1·50 mg, 
administered identically to the 10 µg/kg dose or 3 × 150 µg/kg ondansetron, up to a 
maximum total dose of 32 mg (maximum single dose 10.67 mg: current guidance is that a 
single intravenous dose must not exceed 8 mg), administered as a 15-minute intravenous 
infusion 30 ± 5 minutes before chemotherapy, as well as 4 and 8 hours ± 30 minutes after 
first administration (label-specified administration schedule).  
 
A single palonosetron dose per chemotherapy cycle (day 1) was given to each patient in the 
two palonosetron groups, regardless of whether the chemotherapy regimen was single day 
or multiple day. Three ondansetron doses were given to each patient in the ondansetron 
group on day 1. If a patient was scheduled to receive multiple day chemotherapy, then they 
could receive any permitted prophylactic medication according to the standard practice of 
the investigative site on any other treatment days in the chemotherapy cycle beyond day 1. 
Patients on such schedules, regardless of study treatment group, could therefore potentially 
receive ondansetron on treatment days subsequent to day 1. Patients could receive study 
treatment for up to four chemotherapy cycles. 
 
The ondansetron indication is limited to the management of CINV in children aged ≥6 
months. However, due to the unmet medical need for antiemetics in younger patients, and at 
the request of the FDA, we accepted the inclusion of younger patients in our study. With a 
small number of exceptions (appendix p 3), this off-label use of ondansetron was accepted 
by all relevant regulatory and ethics committees and site investigators. 
 
Study drug solutions were provided in a standard volume of 0.6 mL/kg total body weight and 
transferred into a unique final container. Depending on the final volume as determined by the 
patient’s weight, the final container could be a syringe, a vial, or an infusion bag. The first 
administration, a 15-minute intravenous infusion performed 30 ± 5 minutes before 
chemotherapy, was prepared as described in the appendix (p 4). For the second and third 
administrations of ondansetron (4 and 8 hours ± 30 minutes after the first administration), 
0·075 mL/kg from the ondansetron/placebo ampoule(s) was diluted in isotonic saline solution 
(0·525 mL/kg) to a total volume of 0·6 mL/kg and transferred into the final container. Patients 
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also received concomitant dexamethasone, if deemed appropriate by the site investigator 
unless this was contraindicated or unless corticosteroids were already included in the 
chemotherapy cycle; dosing and administration of corticosteroids were according to standard 
clinical practice. Rescue medication was administered to alleviate established, refractory or 
persistent nausea or vomiting and was permitted on an as-needed basis (metoclopramide 
was not permitted; all other medications were permitted as per the standard of care of the 
site), at the discretion of the site investigator.  
 
Patients were free to withdraw from the study at any time and were not required to provide 
an explanation for their decision to withdraw. Patients could be removed from the study 
without their consent for protocol specified reasons, which included safety concerns or non-
compliance. 
 
Outcomes 
The primary efficacy endpoint was complete response (defined as no vomiting, retching, or 
use of antiemetic rescue medication) during the acute phase (defined as 0–24 hours after 
the start of chemotherapy on day 1) of the first on-study chemotherapy cycle. Secondary 
efficacy endpoints assessed during the first on-study chemotherapy cycle were the 
proportion of patients who achieved a complete response during the delayed (defined as 
>24–120 hours after the start of chemotherapy on day 1) and overall phases (defined as 0–
120 hours after the start of chemotherapy on day 1). Other secondary efficacy endpoints 
assessed for each phase (acute, delayed, and overall) were: the proportion of patients 
without vomiting; the proportion without emetic episodes (defined as one or more continuous 
vomits [expulsion of stomach contents through the mouth] or retches [an attempt to vomit 
that is not productive of stomach contents]); the proportion without antiemetic rescue 
medication; the proportion without nausea (analysis restricted to patients aged ≥6 years); 
time to first vomiting; time to first emetic episode; time to first administration of rescue 
medication; and time to treatment failure (time to first emetic episode or first administration of 
antiemetic rescue medication, whichever occurred first).  
 
In the first on-study treatment cycle, for the assessment of emetic episodes, a diary was 
provided to the patient or their caregivers; one part of the diary was for the acute phase, the 
other for the delayed phase. In the diary, each episode of retching and vomiting, as well as 
any rescue medication administered, was to be entered. Nausea was assessed by a yes/no 
question in the electronic case report form (eCRF). This question was asked to patients of 6 
years of age or older, at the end of the acute and delayed phases (appendix p 3). In 
subsequent chemotherapy cycles, for the acute and delayed phases, both nausea and 
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vomiting were assessed by yes/no questions in the electronic case report form (eCRF). 
Missing data for any single question relating to vomiting and retching, nausea or timing of 
antiemetic rescue medication intake led to an assessment of failure in relation to complete 
response.   
 
Primary and secondary efficacy analyses also included summary statistics by age and 
chemotherapy-related emetogenicity strata. 
 
Safety was assessed on adverse events, physical examinations (performed at screening; 
days -14 to -1, or -7 to -1 if the patient was aged <2 years, and between days 7 to 10), vital 
signs (pulse, systolic and diastolic blood pressures; recorded at screening, day 1 – at the 
end of the first study drug administration, and 1 and 3 hours after the end of the first study 
drug administration –, and between days 7 to 10), laboratory assessments (haematology, 
blood chemistry, and urinalysis; blood samples taken at screening and between days 7 to 10 
for haematology and chemistry assessments; samples for serum chemistry assessments 
were taken on day 1, at the end of the first study drug administration), and 12-lead 
electrocardiograms (recorded in triplicate at screening and between days 7 to 10). In 
addition, a single electrocardiogram was recorded at the end of the first study drug 
administration on day 1. Adverse events were coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), version 14·0. All treatment-emergent adverse events, 
whether non-serious, serious, or adverse drug reactions, had their severity (mild, moderate, 
or severe), intensity (rated according to the descriptions and grading scales of the Common 
Terminology Criteria for Adverse Events [CTCAE], version 4·03), and the site investigator’s 
opinion on their relationship to the study drug, recorded. The period for assessing adverse 
events was specified as up to 18 days after study drug administration on day 1. 
 
Statistical analysis 
The full analysis set comprised all randomised patients who received at least one course of 
moderately or highly emetogenic chemotherapy and an active study drug. The as-treated 
population was similar to the full analysis set, except that the randomised patients were 
analysed according to the actual treatment received. The safety population comprised all 
patients who received at least one dose of study drug and had at least one safety 
assessment. Safety was analysed according to actual treatment received.  
 
The primary efficacy objective was to demonstrate the non-inferiority of palonosetron, versus 
ondansetron, during the acute phase (0–24 hours post-chemotherapy) of the first on-study 
chemotherapy cycle, comparing the difference in the proportions of patients achieving a 
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complete response with palonosetron (πT) minus ondansetron (πR) versus a preset non-
inferiority margin (δ=-15%). To be considered as non-inferior to ondansetron, for at least one 
of the doses of palonosetron, the lower limit of the 97.5% CI for the ∆CR had to be superior 
to -15%. The elementary null hypothesis (H0) of no difference between treatments (tested 
with a type I error of 2·5%) was: 
 
πT -πR  ≤δ.  Divided into two hypotheses, H0 20 µg/kg: πT 20 µg/kg-πR  ≤δ and H0 10 µg/kg: πT 10 µg/kg-πR  
≤δ  
 
The stratum-adjusted Mantel-Haenszel method was used to calculate 97·5% confidence 
intervals (CIs) from the weighted sum of the differences in complete response rate (∆CR). If 
the lowest bounds of the CIs were strictly superior to the non-inferiority margin, the null 
hypothesis was rejected. A stratum-adjusted Mantel-Haenszel analysis of the as-treated 
population and stratum-adjusted Miettinen and Nurminen analyses of the full analysis set 
and as-treated population,28 were also performed as co-primary efficacy analyses. The non-
inferiority assessment applied only to complete response in acute phase for the first on-study 
chemotherapy cycle. No adjustment was done for multiple testing in relation to the 
secondary endpoints. The secondary endpoints were analysed in an exploratory way, by 
comparing the stratum-adjusted Mantel-Haenszel 95% CIs of the proportional difference to 
zero; superiority was considered when the 95% CI of the ∆CR did not include 0. Not being 
included in the powered part of the analysis, these data could not subsequently lead to a 
label claim. 
 
The sample size for this non-inferiority trial was estimated based upon the following 
assumptions: a complete response rate in the palonosetron and ondansetron groups of 60% 
based on previous trial data; type I error of 5% (2-sided); type II error of 20% (power of 
80%); non-inferiority margin, set following discussion with the regulatory authority,29 of -15%. 
Our study was based on the PALO-99-07 study, in which the palonosetron doses of 3 μg/kg 
and 10 μg/kg were tested.30 The dose of 10 μg/kg showed a complete response rate of 
54.1% (20/37 patients) during the acute phase. One exclusion criterion in this study was 
treatment with chemotherapy that required corticosteroids on study day 1. In our study, the 
use of corticosteroid as part of the chemotherapy was permitted, so the expected complete 
response rate was slightly increased to 60%. In the case of ondansetron, efficacy results for 
intravenous administration in a paediatric population, as stated in the FDA label, indicate a 
complete response rate of 58% and 56%. 
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To maintain the overall type I error at 5%, the conservative correction of Bonferroni was 
applied and the 2-sided significance level set to 2·5% for each elementary test. 
Determination of the sample size had to ensure a disjunctive power of at least 80%. This 
was achieved using simulations, which showed that from n=155 the lower bound of the 95% 
CI of the disjunctive power was at least 80% and the estimated power superior to 81·5%. 
Accordingly, the total sample size was increased to 492 evaluable patients, equally 
distributed between the three treatment groups (164 patients per group).  
 
SAS® version 9.2 was used for data analyses. The study is registered with 
ClinicalTrials.gov, number NCT01442376. 
 
Role of the funding source 
The funder of the study was responsible for data management and statistical analysis, and 
designed the study in conjunction with the corresponding author in response to an FDA 
written request. The funder interpreted the data in collaboration with the authors and 
commissioned drafting of the manuscript. The corresponding author had full access to all the 
data in the study and had the final responsibility for the decision to submit for publication. 
 
 
Results 
 
Patients 
Between September 12, 2011, and October 26, 2012, 502 patients were randomly assigned 
to treatment. Eight patients did not receive an active study drug and a further patient 
received chemotherapy of low emetogenic potential; 493 patients were therefore included in 
the full analysis set and as-treated population (for sites enrolling these patients see appendix 
p 5, 6), and 494 in the safety population (figure 1). Baseline characteristics for the full 
analysis set, as summarised in table 1, were generally comparable between the treatment 
groups. In particular, the distribution of primary cancers was essentially balanced. The 
majority of patients received moderately emetogenic chemotherapy, most patients had 
previously received chemotherapy and 271 [55%] of 493 received concomitant 
corticosteroids. Approximately one half of patients (293 [52%] of 493) received on-study 
moderately/highly emetogenic chemotherapy as a single day (day 1) regimen, with about 
three quarter of patients (361 [73%] of 493) treated across multiple days with chemotherapy 
agents, regardless of the emetogenicity (for further detail of administration schedules, see 
appendix p 7). The most frequently administered chemotherapeutic agents in the present 
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study were vinca alkaloids and analogues, and nitrogen mustard analogues (appendix p 8). 
Corticosteroids use during the first on-study chemotherapy cycle was essentially balanced 
between treatment groups and is summarised in the appendix (p 9). Dexamethasone was 
administered for various reason in 32% (106 of 493) of the patients from day 1 to day 6, and 
in 15% (73 of 493) from day 2 to day 6; other corticosteroids were given less frequently. The 
mean dose of dexamethasone administered was 7 mg/m²/day. 
 
Efficacy 
During the acute phase, complete responses were recorded in 90 (54·2%) of 166 patients 
receiving 10 µg/kg palonosetron, 98 (59·4%) of 165 patients receiving 20 µg/kg 
palonosetron, and 95 (58·6%) of 162 patients receiving ondansetron (table 2). The complete 
response rate was therefore lower in the 10 µg/kg palonosetron group than in the 
ondansetron group (∆CR -4·41%; 97·5% CI -16·4–7·6; p=0·024). For the 20 µg/kg 
palonosetron and ondansetron groups the ∆CR was 0·36%, with non-inferiority 
demonstrated for this dose of palonosetron as the lower bound of the 97·5% CI of this 
difference (-11·7–12·4; p=0·0022) was greater than the preset non-inferiority margin (δ=-
15%). These findings were validated by co-primary analyses performed on the full analysis 
set and as-treated population, as detailed in the appendix (p 10).  
 
During the study, corticosteroids were given at some time to 90 (54·2%) of 166 patients 
receiving 10 µg/kg palonosetron. Of these 90 patients, 42 (46·7%) achieved a complete 
response, compared with 48 (63·2%) of 76 patients who were not given corticosteroids. 
Corticosteroids were given to 92 (55·7%) of 165 patients receiving 20 µg/kg palonosetron. 
Of these 92 patients, 57 (62·0%) achieved a complete response, compared with 41 (56·2%) 
of 73 patients who were not given corticosteroids. Corticosteroids were given to 89 (54·9%) 
of 162 patients receiving ondansetron. Of these 89 patients, 55 (61·8%) achieved a 
complete response, compared with 40 (54·8%) of 73 patients who were not given 
corticosteroids (appendix p 11). Analysis of complete response rates per age group and 
chemotherapy-related emetogenicity are presented in the appendix (p 12, 13). No clear 
trends could be identified in efficacy between age groups that might suggest the need for 
dose adjustments based on patient age. The same applied to the analysis by emetogenicity. 
 
During the delayed phase, complete responses were recorded in 48 (28·9%) of 166 patients 
receiving 10 µg/kg palonosetron, 64 (38·8%) of 165 patients receiving 20 µg/kg 
palonosetron, and 46 (28·4%) of 162 patients receiving ondansetron. The complete 
response rates were therefore comparable for the 10 µg/kg palonosetron and ondansetron 
groups (∆CR 0·42%; 95% CI -9·4–10·3), and higher for the 20 µg/kg palonosetron group 
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versus the ondansetron group (∆CR 10·17%; 95% CI -0·1–20·4). It was therefore interesting 
to note, in an additional analysis performed on the as-treated population, that the 95% CI 
calculated for the difference between the 20 µg/kg palonosetron and ondansetron groups 
(∆CR 11·02%; 95% CI 0·8–21·2) did not include a zero value, indicating that the efficacy of 
this dose of palonosetron during the delayed phase may be superior to that of ondansetron 
(appendix p 10).  
 
The proportional differences in complete response rate recorded during the overall phase 
were similar to those recorded during the delayed phase, with the 20 µg/kg dose of 
palonosetron being more effective at achieving a complete response than ondansetron 
(table 2). 
 
In order to further explore the efficacy of study treatments and avoid possibly confounding 
effects of multiple day chemotherapy in the delayed phase analysis, an exploratory 
investigation of outcome in the first on-study chemotherapy cycle was carried out in the 
subset of 254 [52%] of 493 patients who received highly or moderately emetogenic 
chemotherapy only on day 1 of the on-study chemotherapy regimen (appendix p 14). In each 
of the acute, delayed and overall phases, higher complete response rates were seen in the 
20 µg/kg palonosetron group compared with the 10 µg/kg palonosetron and ondansetron 
groups.  
 
The proportion of patients who experienced no vomiting in the full analysis set was higher in 
both palonosetron groups during all phases compared with the ondansetron group (table 3). 
In particular, the proportions in the 20 µg/kg palonosetron group were higher during the 
acute (∆10·03%; 95% CI 1·2–18·8), delayed (∆15·84%; 95% CI 5·7–26·0), and overall 
phases (∆17·46%; 95% CI 7·0–27·9) (table 3). 
 
From the proportions of patients reporting no emetic episodes, greater efficacy was 
demonstrated for the 20 µg/kg dose of palonosetron than for ondansetron during the acute 
(∆11·25%; 95% CI 2·0–20·5), delayed (∆15·38%; 95% CI 5·1–25·7), and overall (∆17·56%; 
95% CI 7·0–28·1) phases (table 3). For both no vomiting and no emetic episodes endpoints 
the 95% CIs of the ∆ did not include a zero value, indicating that the efficacy of this dose of 
palonosetron may be superior to that of ondansetron. 
 
The number of patients receiving rescue medication and the type of medication administered 
was similar across the treatments groups. The proportion of patients who avoided antiemetic 
rescue medication was lower in the 10 µg/kg palonosetron group during the acute phase, 
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and comparable during the delayed and overall phases, versus the ondansetron group. The 
proportion of patients in the 20 µg/kg palonosetron group who avoided antiemetic rescue 
medication was comparable during the acute phase (∆-1·23%; 95% CI -10·8–8·3), but 
higher during the delayed (∆9·97%; 95% CI -0·6–20·6) and overall phases (∆8·04%; 95% CI 
-2·5–18·5), versus the ondansetron group (table 3). 
 
The proportion of patients that did not experience nausea was lower in the 10 µg/kg 
palonosetron group during the acute phase and higher during the delayed and overall 
phases, compared with the ondansetron group (table 3). The proportion of patients with no 
nausea in the 20 µg/kg palonosetron group was marginally higher during the acute phase 
(∆4·97%; 95% CI -7·7–17·7) and higher during the delayed (∆14·79%; 95% CI 1·5–28·1) 
and overall (∆15·00%; 95% CI 1·4–28·6) phases compared with the ondansetron group. For 
the nausea endpoint, the 95% CI of the ∆ did not include a zero value, indicating that the 
efficacy of this dose of palonosetron during the delayed and overall phases may be superior 
to that of ondansetron. 
 
Safety 
The incidence of treatment-emergent adverse events in the first on-study treatment cycle 
was lower in the 20 µg/kg palonosetron group (113 [69·3%] of 163 patients), than in the 10 
µg/kg palonosetron group (134 [80·2%] of 167 patients), and the ondansetron group (134 
[81·7%] of 164 patients) (table 4); for seven patients in each treatment group, these were 
deemed to be drug-related by the investigator, the most common being headache, which 
accounted for three (1·8%) of 167 patients receiving 10 µg/kg palonosetron, one (<1%) of 
163 patients receiving 20 µg/kg palonosetron, and two (1·2%) of 164 patients receiving 
ondansetron (table 5). Only one drug-related event in one (<1%) of 163 patients in the 20 
µg/kg palonosetron group in this first on-study cycle was grade 3 or above (grade 4 infusion 
site pain). No patients discontinued due to drug-related adverse events. Regarding cardiac 
disorders, sinus tachycardia accounted for one (<1%) of 167 patients receiving 10 µg/kg 
palonosetron and two (1·2%) of 164 patients receiving ondansetron, while conduction 
disorder accounted for one (<1%) of 167 patients receiving 10 µg/kg palonosetron and one 
(<1%) of 164 patients receiving ondansetron. Electrocardiogram QT prolonged accounted 
for one (<1%) of 163 patients in the 20 µg/kg palonosetron group and two (1·2%) of 164 
patients receiving ondansetron (table 5). The treatment-emergent adverse events recorded 
in the first on-study chemotherapy cycle and occurring in ≥2% of patients are presented in 
the appendix (p 15). Treatment emergent adverse events of grade 1–2 in 10% or more of 
patients in any treatment group, or at grades 3–5 in one or more patients in any treatment 
group across all on-study treatment cycles are reported in the appendix (p16–20). 
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The incidence of serious adverse events in the first on-study treatment cycle was lower in 
the 20 µg/kg palonosetron group (43 [26·4%] of 163 patients) than the 10 µg/kg 
palonosetron group (52 [31·1%] of 167 patients), and the ondansetron group (55 [33·5%] of 
164 patients) (table 4). All were considered to be unrelated to the study drug. Three patients 
developed adverse events during the first on-study chemotherapy cycle that led to fatal 
outcomes; one patient receiving ondansetron and highly emetogenic chemotherapy 
experienced multi-organ failure, pulmonary haemorrhage and staphylococcal sepsis and 
died on day 15 after initial dosing, one patient receiving ondansetron and moderately 
emetogenic chemotherapy developed febrile neutropenia and candidiasis and died of a 
multi-organ failure on 25 day after initial dosing and a third patient receiving 20 µg/kg 
palonosetron and undergoing moderately emetogenic chemotherapy developed both brain 
oedema and haemorrhagic stroke on day 1 and died 40 days after initial dosing of multi-
organ failure. Four additional patients developed adverse events leading to fatal outcomes 
after the first on-study chemotherapy cycle. Two deaths occurred in patients in the 20 µg/kg 
palonosetron group (one due to cardiac arrest and one due to neoplastic progression), and 
two deaths occurred in patients in the ondansetron group, both due to respiratory failure 
(one 28 days after receiving the second cycle of ondansetron and one 89 days after initial 
dosing). No deaths were considered to be related to study drug. 
 
 
Discussion 
 
Overall, the results of the present study demonstrated that palonosetron, administered at a 
dose of 20 µg/kg, was non-inferior to ondansetron (a commonly administered therapy) in the 
prevention of CINV in paediatric cancer patients, aged between 2·1 months (we were unable 
to enrol neonates) and 16·9 years, during the acute phase of moderately or highly 
emetogenic chemotherapy regimens. Furthermore, as supported by an exploratory analysis 
of the subgroup of patients who received a single day (day 1) on-study chemotherapy 
regimen, the study data suggest that palonosetron, may be more effective than ondansetron 
during the delayed phase in relation to preventing both vomiting and nausea (conclusions of 
nausea analysis relate to patients aged 6 years or over). This finding is particularly 
significant given that the prevention and optimal delay of CINV remains a clinically unmet 
need, a problem exacerbated by its occurrence generally after hospital discharge, while the 
patient is not under direct observation.5 Palonosetron could therefore potentially provide 
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much needed relief to paediatric cancer patients for up to five days after they have 
undergone chemotherapy, and following discharge from hospital. 
 
The proportion of patients achieving a complete response was similar for those who did and 
did not receive concomitant corticosteroids in the 20 µg/kg palonosetron and ondansetron 
groups, although marginally higher in each case in those who received corticosteroids. 
Conversely, the number of patients achieving a complete response in the 10 µg/kg 
palonosetron group was higher for those who did not receive corticosteroids (63·2% versus 
46·7% with corticosteroids). It is unclear whether this difference is clinically meaningful or 
simply due to random variation. 
 
With respect to safety, the types of treatment-emergent adverse events recorded were 
similar across the three treatment groups. However, a lower incidence of such events was 
recorded in the 20 µg/kg palonosetron group compared with the ondansetron group and the 
10 µg/kg palonosetron group. The treatment-emergent adverse events most frequently 
reported were consistent with those most commonly observed in cancer patients undergoing 
chemotherapy; (MedDRA system organ class) blood and lymphatic system disorders, 
gastrointestinal disorders, and general disorders and administrative site conditions (appendix 
p 15). The incidence of serious adverse events was also similar across the three treatment 
groups, with those most frequently recorded, blood and lymphatic system disorders and 
infections and infestations, also being consistent with those most commonly observed in 
cancer patients undergoing chemotherapy. The lower incidence of both, treatment-emergent 
and serious adverse events in the 20 µg/kg palonosetron group compared with the 
ondansetron group raises the possibility that the safety profile of this particular dose of 
palonosetron may be better than that of ondansetron.  
 
The majority of treatment-emergent adverse events recorded in each treatment group were 
deemed by the investigators not to be study drug-related. The most frequently recorded 
study drug-related treatment-emergent adverse events were (MedDRA system organ class) 
nervous system disorders, mainly (MedDRA preferred term) headache. With respect to 
electrocardiogram abnormalities, it is important to note that in contrast to historical studies in 
adult cancer patients, the incidence of prolonged QT interval was low in the ondansetron 
group in this study (two [1%] of 164 patients).13,14 Similarly, the incidence in the palonosetron 
groups was low, with this event reported for only one (<1%) of 163 patients in the 20 µg/kg 
group. Throughout the entire study, no study drug related treatment-emergent adverse 
events with a fatal outcome were recorded, and no patients discontinued the study due to 
drug-related treatment-emergent adverse events. 
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To date, few studies have been conducted into the prevention of CINV in paediatric patients, 
and most involve the 5-HT3 receptor antagonists granisetron and ondansetron.
31-33 However, 
palonosetron has been evaluated in one comparative study versus ondansetron and was 
shown to be safe, efficacious and cost-effective.34 Other non-controlled studies reported that 
palonosetron, dosed according to patient's weight at 3 µg/kg and 10 µg/kg, was effective and 
well tolerated in the paediatric population,30 and that a single dose of 5 µg/kg of 
palonosetron without concomitant corticosteroid treatment was effective in preventing both 
acute and delayed phase CINV in the majority of children with acute lymphoblastic 
leukaemia treated with high-dose methotrexate.35  
 
The inclusion of patients scheduled to receive multiple day (day 1 and additional day[s]) 
chemotherapy was necessary to enrol enough patients in this large study, given that many 
paediatric chemotherapy regimens are multiple day; this could potentially have impacted on 
the evaluation of efficacy. The possibility that the site investigator could make decisions 
according to local practice, in relation to the use of and dose of 
dexamethasone/corticosteroids administered, was also a study limitation. However, the 
chosen model of randomisation and double blind permits these limitations to be overcome 
when comparing the study treatment groups. In addition we chose not to stratify by use of 
dexamethasone and schedule of chemotherapy (single day vs multiple day), so as not to 
increase the number of factors, which might have led to incomplete strata and subsequent 
problems in the efficacy analysis. 
 
In line with the promising earlier studies, of palonosetron in the paediatric setting, the results 
of our study showed palonosetron administered at a single dose of 20 µg/kg to be non-
inferior to multiple daily doses of ondansetron 150 µg/kg in paediatric patients receiving 
moderately or highly emetogenic chemotherapy. In addition, we found that palonosetron at a 
standard dose of 20 µg/kg does not need to be dose adjusted depending on the patient's 
age. These results led to the approval of the 20 µg/kg dose of palonosetron by both the 
United States FDA and the European Medicines Agency for the prevention of CINV in 
paediatric cancer patients aged one month to <17 years undergoing initial or repeated 
courses of moderately or highly emetogenic chemotherapy. This approval was also to our 
knowledge the first for an agent capable of preventing acute CINV in patients aged between 
one and six months (ondansetron is indicated for the management of CINV in children aged 
between ≥6 months and 18 years). As a substantial fraction of cancers in children are 
diagnosed during the first year of life,36 this approval provides a vital new option for children, 
and especially infants undergoing emetogenic chemotherapy regimens. Also, it has recently 
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been suggested that the addition of the oral NK1 receptor antagonist aprepitant to 
ondansetron with or without dexamethasone may be effective in the prevention of CINV in 
paediatric patients aged 6 months to 17 years receiving moderately or highly emetogenic 
chemotherapy regimens.37 A similar study of palonosetron with aprepitant would be of 
interest. 
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Panel: Research in context 
 
Evidence before this study  
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The potential efficacy and good safety profile of the 5-HT3 receptor antagonist, palonosetron, 
in the management of chemotherapy-induced nausea and vomiting (CINV) in patients 
receiving moderately or highly emetogenic chemotherapy, as demonstrated in publications 
comparing palonosetron with ondansetron, dolasetron and granisetron in adult patients, led 
to studies of the efficacy of palonosetron in paediatric patients with cancer undergoing 
moderately or highly emetogenic chemotherapy. A search of PubMed (with no time 
restrictions), abstracts of major oncology and supportive care conferences and 
ClinicalTrials.gov revealed only one full publication and one abstract reporting on the efficacy 
of palonosetron in preventing CINV in children undergoing chemotherapy. Indeed the 
authors of Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline 
Update (2011) noted that there was limited research evidence on nausea and vomiting 
control in special populations, particularly paediatric patients. 
 
This, together with the encouraging results from the study of 100 paediatric patients with 
cancer undergoing chemotherapy, in which patients were treated either with palonosetron 
(n=50) or ondansetron (n=50) and monitored for emesis and nausea, led to the decision to 
undertake a multicentre, randomised, double-blind phase 3 study of palonosetron in a large 
paediatric population. Ondansetron was chosen as the active comparator because it is one 
of the most frequently prescribed antiemetic agents and is approved in many countries for 
intravenous and oral use in adults and children for the prevention of CINV. Additional 
antiemetics with a CINV indication by the EMA are ondansetron in CINV paediatric patients 
≥6 months old and adolescents and granisetron approved in paediatric patients between ≥2 
years and 18 years old developing CINV. 
 
Added value of this study 
CINV continues to be a distressing side-effect of moderately and highly emetogenic 
chemotherapy. Antiemetics currently in use include 5-HT3 receptor antagonists, NK1 receptor 
antagonists, and corticosteroids. Such agents are generally used in combination. 
Palonosetron, has an up to 100-times higher affinity for the 5-HT3 receptor and a significantly 
longer half-life, compared with antagonists such as ondansetron, and is therefore potentially 
more clinically effective. As a single agent in adult patients, palonosetron is more effective 
than ondansetron and dolasetron at preventing acute and delayed CINV due to moderately 
emetogenic chemotherapy, and when used in combination with dexamethasone, provides 
superior control versus ondansetron and granisetron at preventing delayed CINV due to 
highly emetogenic chemotherapy. Palonosetron is approved in several countries for the 
prevention of CINV in adult patients following initial and repeated courses of moderately and 
highly emetogenic chemotherapy. Its safety and efficacy in children has also been 
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demonstrated in preliminary studies. The current study is part of a paediatric development 
programme requested by the US Food and Drug Administration and investigates two doses 
of palonosetron for the prevention of CINV due to moderately or highly emetogenic 
chemotherapy in paediatric patients. 
 
Implications 
The results from the present trial (to our knowledge one of the largest examining the 
supportive care of paediatric oncology patients undergoing chemotherapy) showed that 
single-dose 20 μg/kg palonosetron was an effective prophylactic treatment for CINV in 
paediatric patients aged 0–<17 years, being non-inferior to multiple-dose ondansetron (a 
commonly administered prophylactic treatment) during the acute phase of moderately or 
highly emetogenic chemotherapy and potentially superior to ondansetron during the delayed 
and overall phases. At the 10 μg/kg dose, similar efficacy to ondansetron was observed 
during the delayed and overall phases. The results of this study led to approval of 20 μg/kg 
palonosetron by the US Food and Drug Administration and the European Medicines Agency 
for the prevention of CINV in paediatric patients aged from one month to <17 years – to our 
knowledge, the first approval of an agent capable of preventing acute CINV in patients aged 
one to six months. 
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Figure 1. Trial profile 
502 patients randomly assigned
169 to 10 µg/kg palonosetron
169 to 20 µg/kg palonosetron
164 to ondansetron
167 included in the SAF 163 included in the SAF 164 included in the SAF
166 assigned to 10 µg/kg 
palonosetron (FAS)
165 assigned to 20 µg/kg 
palonosetron (FAS)
162 assigned to 
ondansetron (FAS) 
1 underwent LEC
8 did not receive study drug
4 vomiting
2 chemotherapy not administered
1 central line infection
1 incorrect body weight
166 included in the 
as-treated population
163 included in the 
as-treated population
164 included in the 
as-treated population
1 received ondansetron
1 received ondansetron
1 received 10 µg/kg 
palonosetron
 
 
FAS=full analysis set; LEC=chemotherapy of low emetogenicity; SAF=safety population.  
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Table 1. Patient baseline and disease characteristics (full analysis set) 
 
Palonosetron 
10 µg/kg 
(n=166) 
Palonosetron 
20 µg/kg 
(n=165) 
Ondansetron 
3 × 150 µg/kg 
(n=162) 
Gender 
Male 
Female 
 
88 (53%) 
78 (47%) 
 
76 (46%) 
89 (54%) 
 
98 (60%) 
64 (40%) 
Ethnic origin 
White (not Hispanic) 
White (Hispanic) 
Mixed: white and Native Indian (Hispanic) 
Asian (not Hispanic) 
Black or African-American (not Hispanic) 
Latino (Hispanic) 
 
136 (82%) 
20 (12%) 
5 (3%) 
2 (1%) 
2 (1%) 
1 (<1%) 
 
139 (84%) 
15 (9%) 
11 (7%) 
0 
0 
0 
 
150 (93%) 
9 (6%) 
3 (2%) 
0 
0 
0 
Age, years 
Mean (SD) 
Median 
Range 
 
8·07 (4·81) 
7·08 
0·21–16·87 
 
8·39 (4·91) 
7·85 
0·24–16·87 
 
8·18 (5·17) 
6·62 
0·18–16·92 
ECOG PS 
Number that underwent an assessment 
Grade 0 
Grade 1 
Grade 2 
 
60 (36%) 
18 (30%) 
36 (60%) 
6 (10%) 
 
70 (42%) 
28 (40%) 
38 (54%) 
4 (6%) 
 
61 (38%) 
24 (39%) 
36 (59%) 
1 (2%) 
Receipt of prior medications* 
Prior antiemetic medications 
Prior medications excluding antiemetics 
 
72 (43%) 
113 (68%) 
 
77 (47%) 
129 (78%) 
 
71 (44%) 
127 (78%) 
Naïvety to chemotherapy 
Naïve 
Non-naïve  
 
39 (23%) 
127 (77%) 
 
35 (21%) 
130 (79%) 
 
31 (19%) 
131 (81%) 
Stratification by emetogenicity and age  
MEC 
 
<2 years 
2–<6 years 
6–<12 years 
12–<17 years 
8 (5%) 
35 (21%) 
32 (19%) 
37 (22%) 
8 (5%) 
40 (24%) 
33 (20%) 
35 (21%) 
9 (6%) 
36 (22%) 
33 (20%) 
33 (20%) 
HEC <2 years 
2–<6 years 
6–<12 years 
12–<17 years 
7 (4%) 
19 (11%) 
14 (8%) 
14 (8%) 
7 (4%) 
14 (8%) 
13 (8%) 
15 (9%) 
6 (4%) 
18 (11%) 
11 (7%) 
16 (10%) 
On-study chemotherapy schedule (MEC/HEC 
agents only) 
Day 1 only 
Day 1 and another day(s) (2–6)
‡
  
 
 
79 (48%) 
87 (52%) 
 
 
83 (50%) 
82 (50%) 
 
 
92 (57%) 
70 (43%) 
Tumour extent at study entry 
Primary disease 
Metastatic disease 
Local recurrence 
 
112 (67%) 
47 (28%) 
7 (4%) 
 
118 (72%) 
38 (23%) 
9 (5%) 
 
113 (70%) 
41 (25%) 
8 (5%) 
Most common primary cancers
†
 
Acute lymphocytic leukaemia  
Nephroblastoma  
Rhabdomyosarcoma  
Neuroblastoma  
Medulloblastoma  
B precursor type acute leukaemia  
Ewing's sarcoma  
Hodgkin's disease  
Bone sarcoma  
Non-Hodgkin's lymphoma  
 
18 (11%)  
17 (10%)  
17 (10%)  
13 (8%)  
14 (8%)  
11 (7%)  
5 (3%)  
8 (5%)  
8 (5%)  
2 (1%)  
 
21 (13%)  
15 (9%)  
8 (5%)  
10 (6%)  
10 (6%)  
8 (5%)  
11 (7%)  
10 (6%)  
11 (7%)  
6 (4%)  
 
23 (14%)  
7 (4%)  
13 (8%)  
11 (7%)  
9 (6%)  
12 (7%)  
9 (6%)  
6 (4%)  
3 (2%)  
7 (4%)  
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Hodgkin's disease nodular sclerosis stage 
unspecified  
Primitive neuroectodermal tumour  
Hodgkin's disease mixed cellularity stage 
unspecified  
Acute myeloid leukaemia  
Ependymoma malignant  
Optic tract glioma  
T-cell type acute leukaemia 
Other  
Missing 
1 (<1%)  
 
4 (2%)  
4 (2%)  
 
5 (3%)  
0 
1 (<1%)  
0 
37 (22%) 
1 (<1%) 
8 (5%)  
 
2 (1%)  
2 (1%)  
 
2 (1%)  
2 (1%)  
5 (3%)  
2 (1%) 
29 (18%) 
3 (2%) 
2 (1%)  
 
5 (3%)  
3 (2%)  
 
0 
5 (3%)  
1 (<1%)  
5 (3%) 
39 (24%) 
2 (1%) 
Data are n (%) unless otherwise stated. *Taken within 14 days prior to day 1 of the first on-study 
chemotherapy cycle. 
†
Reported in ≥2% of patients in any treatment group. 
‡
The number of patients receiving 
moderately or highly emetogenic chemotherapy on day 1 and at least one other day (2–6) in the first on-study 
chemotherapy cycle calculated by subtracting the number of patient in the subset receiving chemotherapy only 
on day 1 from the total number in the full analysis set.  
ECOG PS=Eastern Cooperative Oncology Group performance status; HEC=highly emetogenic chemotherapy; 
MEC=moderately emetogenic chemotherapy; SD=standard deviation. 
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Table 2. Complete response rates during all phases of the first on-study chemotherapy cycle 
(full analysis set) 
 
 
Palonosetron 
10 µg/kg 
(n=166) 
Palonosetron 
20 µg/kg 
(n=165) 
Ondansetron 
3 × 150 µg/kg 
(n=162) 
Acute phase 
Patients with CR 
∆CR* 
97·5% CI (MH analysis) 
p-value 
 
90 (54·2%) 
-4·41% 
-16·4–7·6 
0·024 
 
98 (59·4%) 
0·36% 
-11·7
†
–12·4 
0·0022 
 
95 (58·6%) 
 
Delayed phase 
Patients with CR 
∆CR* 
95% CI (MH analysis) 
 
48 (28·9%) 
0·42% 
-9·4–10·3 
 
64 (38·8%) 
10·17% 
-0·1–20·4 
 
46 (28·4%) 
 
 
Overall phase 
Patients with CR 
∆CR* 
95% CI (MH analysis) 
 
39 (23·5%) 
-0·60% 
-10·0–8·8 
 
54 (32·7%) 
8·25% 
-1·6–18·1 
 
39 (24·1%) 
*∆CR=weighted sum of ∆complete response rate palonosetron group minus weighted sum of 
∆complete response rate ondansetron group. 
†
Greater than the preset non-inferiority margin (-15%). 
CI=confidence interval; CR=complete response; MH=Mantel-Haenszel. 
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Table 3. Proportions of patients with no vomiting or emetic episodes, and who avoided 
antiemetic rescue medication, during all phases of the first on-study chemotherapy cycle (full 
analysis set) 
 
 
Palonosetron 
10 µg/kg 
(n=166) 
Palonosetron 
20 µg/kg 
(n=165) 
Ondansetron 
3 × 150 µg/kg 
(n=162) 
Acute phase 
Patients with no vomiting 
∆* 
95% CI 
Patients with no emetic episodes 
∆* 
95% CI 
Patients avoiding antiemetic rescue medication 
∆* 
95% CI 
 
133 (80·1%) 
6·60% 
-2·4–15·7 
122 (73·5%) 
5·12% 
-4·5–14·7 
115 (69·3%) 
-6·83% 
-16·4–2·8 
 
138 (83·6%) 
10·03% 
1·2–18·8 
132 (80·0%) 
11·25% 
2·0–20·5 
124 (75·2%) 
-1·23% 
-10·8–8·3 
 
119 (73·5%) 
 
 
111 (68·5%) 
 
 
123 (75·9%) 
 
 
 
Patients aged ≥6 years with no nausea 
∆* 
95% CI 
(n=97) 
63 (64·9%) 
-2·02% 
-14·7–10·7 
(n=96) 
69 (71·9%) 
4·97% 
-7·7–17·7 
(n=93) 
62 (66·7%) 
Delayed phase 
Patients with no vomiting 
∆* 
95% CI 
Patients with no emetic episodes 
∆* 
95% CI 
Patients avoiding antiemetic rescue medication 
∆* 
95% CI 
 
113 (68·1%) 
10·08% 
-0·1–20·3 
102 (61·4%) 
8·46% 
-1·9–18·8 
64 (38·6%) 
3·21% 
-7·3–13·7 
 
122 (73·9%) 
15·84% 
5·7–26·0 
113 (68·5%) 
15·38% 
5·1–25·7 
75 (45·5%) 
9·97% 
-0·6–20·6 
 
94 (58·0%) 
 
 
86 (53·1%) 
 
 
57 (35·2%) 
 
 
 
Patients aged ≥6 years with no nausea 
∆* 
95% CI 
(n=97) 
55 (56·7%) 
5·86% 
-7·7–19·5 
(n=96) 
63 (65·6%) 
14·79% 
1·5–28·1 
(n=93) 
47 (50·5%) 
Overall phase 
Patients with no vomiting 
∆* 
95% CI 
Patients with no emetic episodes 
∆* 
95% CI 
Patients avoiding antiemetic rescue medication 
∆* 
95% CI 
 
98 (59·0%) 
7·97% 
-2·6–18·5 
87 (52·4%) 
7·00% 
-3·6–17·6 
60 (36·1%) 
2·63% 
-7·8–13·0 
 
114 (69·1%) 
17·46% 
7·0–27·9 
105 (63·6%) 
17·56% 
7·0–28·1 
69 (41·8%) 
8·04% 
-2·5–18·5 
 
83 (51·2%) 
 
 
74 (45·7%) 
 
 
54 (33·3%) 
 
 
 
Patients aged ≥6 years with no nausea 
∆* 
95% CI 
(n=97) 
46 (47·4%) 
4·21% 
-9·3–17·7 
(n=96) 
56 (58·3%) 
15·00% 
1·4–28·6 
(n=93) 
40 (43·0%) 
 
*∆=weighted sum of percentage incidence palonosetron group minus weighted sum of percentage incidence 
ondansetron group. 
CI=confidence interval. 
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Table 4. Treatment-emergent adverse events recorded in the first on-study chemotherapy 
cycle (safety population) 
 
Palonosetron 
10 µg/kg 
(n=167) 
Palonosetron  
20 µg/kg 
(n=163) 
Ondansetron 
3 × 150 µg/kg 
(n=164) 
At least one TEAE 
At least one drug-related TEAE 
At least one SAE 
At least one drug-related SAE 
At least one severe AE 
At least one drug-related severe AE 
Fatal TEAE 
Fatal drug-related TEAE 
Withdrawals due to TEAE 
Withdrawals due to drug-related TEAE 
134 (80·2%) 
7 (4·2%) 
52 (31·1%) 
0 
41 (24·6%) 
0 
0 
0 
0 
0 
113 (69·3%) 
7 (4·3%) 
43 (26·4%) 
0 
34 (20·9%) 
0 
1 (<1%) 
0 
2 (1·2%) 
0 
134 (81·7%) 
7 (4·3%) 
55 (33·5%) 
0 
41 (25·0%) 
0 
2 (1·2%) 
0 
1 (<1) 
0 
Data are n (%). 
AE=adverse event; SAE=serious adverse event; TEAE=treatment-emergent adverse event. 
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Table 5. Drug-related treatment-emergent adverse by MedDRA system organ class and 
preferred term in the first on-study chemotherapy cycle (safety population) 
MedDRA SOC 
MedDRA PT 
 
Palonosetron 
10 µg/kg 
(n=167) 
Palonosetron  
20 µg/kg 
(n=163) 
Ondansetron 
3 × 150 µg/kg 
(n=164) 
At least one drug-related TEAE 7 (4·2%) 7 (4·3%) 7 (4·3%) 
Nervous system disorders 
Headache 
Dizziness 
Dyskinesia   
3 (1·8%) 
3 (1·8%) 
1 (<1%) 
0 
3 (1·8%) 
1 (<1%) 
1 (<1%) 
1 (<1%) 
2 (1·2%) 
2 (1·2%) 
0 
0 
Cardiac disorders 
Sinus tachycardia 
Conduction disorder 
1 (<1%) 
1 (<1%) 
1 (<1%) 
0 
0 
0 
2 (1·2%) 
2 (1·2%) 
1 (<1%) 
Investigations 
Electrocardiogram QT prolonged 
0 
0 
1 (<1%) 
1 (<1%) 
2 (1·2%) 
2 (1·2%) 
Skin and subcutaneous tissue disorders 0 2 (1·2%) 1 (<1%) 
General disorders and administrative site conditions 1 (<1%) 1 (<1%) 0 
Musculoskeletal and connective tissue disorders 0 0 1 (<1%) 
Respiratory, thoracic, and mediastinal disorders 2 (1·2%) 0 0 
Data are n (%). 
PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event. 
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